
EU Regulators Recommend Not Releasing Batches of Janssen COVID-19 Vaccine
As a safety measure, supervisory authorities in the European Union have recommended not releasing batches of Janssen’s COVID-19 vaccine with API manufactured at Emergent BioSolutions’ Maryland facility.
The European Medicines Agency (EMA)
Vaccine production was suspended at Emergent’s Bayview, Md. facility in April 2021 after a manufacturing error caused loss of product and an
EMA stated in a press release that it is working with FDA and international partners to ensure the quality of COVID-19 vaccines.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.